Trial
NCT05339087
Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Heidelberg University
Collaborators
Merck Sharp & Dohme LLC
Condition
Pulmonary Vascular Disorder
Intervention
Riociguat Oral Tablet
Why stopped
Strategic re-prioritization by the IMP supplier. Decision not safety-related.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-21